Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis

Table 1 Patients’ characteristics in this study

Characteristics
Age (yr, mean ± SD)	16-82 (38.7 ± 16.7)
Sex	Male 29, female 26
Disease duration from diagnosis (mo, mean ± SD)	1-384 (59.4 ± 78.8)
Disease extent
Left-sided colitis	12
Pancolitis	43
Disease refractory type
Steroid-dependent	33
Steroid-refractory	21
Refusal of steroids	1
Clinical type
One-attack	4
Relapsing-remitting	50
Chronic continuous	1
Mean CAI (mean ± SE) (pre first course of CAP)	9.0 ± 0.62
Mean DAI (mean ± SE) (pre first course of CAP)	11.3 ± 0.55
Medication (pre first course of CAP)
PSL (oral)	Yes 54, no 1
5-ASA	Yes 52, no 3
Thiopurines	Yes 12, no 43
TNF-α antibodies	Yes 1 (adalimumab), no 54
Vedolizumab, tofacitinib, tacrolimus, ustekinumab	Yes 0, no 55
Dose of PSL at the start of CAP (mean ± SD)	0-60 mg (33.4 ± 19.2)
Type of CAP	GMA 38, LCAP 17
Observation period after the first course of CAP (mo, mean ± SD)	18-193 (81.5 ± 47.3)

CAI: Lichtiger’s clinical activity index; DAI: Sutherland index (disease activity index); PSL: Prednisolone; 5-ASA: 5-Aminosalicylic acid; CAP: Cytapheresis; GMA: Granulocyte and monocyte adsorptive apheresis; LCAP: Leukocytapheresis.